If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solutionThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Based on its mechanism of action, ramucirumab can cause fetal harm when administered to a pregnant woman. There are no available data on ramucirumab use in pregnant women.1 Animal models link
angiogenesis
VEGF, and
VEGFR-2
to critical aspects of
female reproduction
embryo-fetal development, and
postnatal development.1
No animal studies have been conducted to evaluate the effect of ramucirumab on reproduction and fetal development. Advise a pregnant woman of the potential risk to a fetus. In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%, respectively.1
Based on its mechanism of action, ramucirumab can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ramucirumab and for 3 months after the last dose.1
Lactation Risk Summary
There is no information on ramucirumab regarding its
presence in human milk
effects on the breastfed child, or
impact on milk production.1
Human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts. Because of the potential risk for serious adverse reactions in breastfed children from ramucirumab, advise women not to breastfeed during treatment with ramucirumab and for 2 months after the last dose.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
IgG = immunoglobulin G
VEGF = vascular endothelial growth factor
VEGFR-2 = vascular endothelial growth factor receptor 2
Date of Last Review: March 20, 2019
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST